Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma

BACKGROUND: More than 400 preclinical studies report ≥ 1 compound as cytotoxic to multiple myeloma (MM) cells; however, few of these agents became relevant in the clinic. Thus, the utility of such assays in predicting future clinical value is debatable. PATIENTS AND METHODS: We examined the applicat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kortuem, K. Martin, Zidich, Kaitlyn, Schuster, Steven R., Khan, Meaghan L., Jimenez-Zepeda, Victor H., Mikhael, Joseph R., Fonseca, Rafael, Stewart, A. Keith
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4092053/
https://ncbi.nlm.nih.gov/pubmed/24565465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.12.015
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller